Management of anticoagulation around pacemaker and defibrillator surgery.
From the University of Ottawa Heart Institute, Ottawa, ON, Canada (D.H.B.); Population Health Research Institute, Hamilton, ON, Canada (J.S.H.); and McGill University Health Center and Hôpital Sacré-Coeur de Montréal, Montreal, QC, Canada (V.E.). dbirnie@ottawaheart.ca.
David H
DH
Birnie
From the University of Ottawa Heart Institute, Ottawa, ON, Canada (D.H.B.); Population Health Research Institute, Hamilton, ON, Canada (J.S.H.); and McGill University Health Center and Hôpital Sacré-Coeur de Montréal, Montreal, QC, Canada (V.E.).
Jeff S
JS
Healey
From the University of Ottawa Heart Institute, Ottawa, ON, Canada (D.H.B.); Population Health Research Institute, Hamilton, ON, Canada (J.S.H.); and McGill University Health Center and Hôpital Sacré-Coeur de Montréal, Montreal, QC, Canada (V.E.).
Vidal
V
Essebag
D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D000991:Antithrombins / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications / Q000628:therapy*; D001562:Benzimidazoles / Q000627:therapeutic use; D000069604:Dabigatran; D017147:Defibrillators, Implantable / Q000009:adverse effects*; D006801:Humans; D020766:Intracranial Embolism / Q000209:etiology* / Q000517:prevention & control; D008297:Male; D010138:Pacemaker, Artificial / Q000009:adverse effects*; D014859:Warfarin / Q000627:therapeutic use*; D015091:beta-Alanine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin; D000069604:Dabigatran